摘要
目的：探讨Ⅱ/Ⅲ期结肠癌术后辅助化疗疗效与生存时间。方法选取108例Ⅱ/Ⅲ期结肠癌术后辅助化疗患者作为研究组，选取同期52例仅接受单纯手术治疗的Ⅱ/Ⅲ期结肠癌患者作为对照组，分析两组疗效及随访两组患者生存时间。结果两组患者随访3年，研究组中位无病生存时间18个月，无病生存率为69．44％，复发转移病例26例，占24．07％，死亡7例，占6．48％；对照组中位无病生存时间12个月，无病生存率为46．15％，复发转移病例18例，占34．62％，死亡10例，占19．23％，研究组中位无病生存时间和复发转移均明显优于于对照组（χ2＝8．07、4．74，均P＜0．05）。术后辅助化疗患者毒副反应主要以恶心呕吐、食欲不振、神经毒性及脱发多见，但均比较轻，严重者甚少，大多数患者可耐受。结论Ⅱ/Ⅲ期结肠癌患者术后进行辅助化疗，可降低术后复发转移，延长患者的生存时间。
Objective To study the efficacy of stageⅡ/Ⅲcolon cancer postoperative adjuvant chemotherapy and survival time.Methods 108 stage Ⅱ/Ⅲ colon cancer patients with postoperative adjuvant chemotherapy were selected as the study group,and in the same period 52 stage Ⅱ/Ⅲ colon cancer patients with only simple surgery treatment were selected as the control group.The adjuvant curative effect of the two groups were analyzed and the sur-vival time was followed up.Results The patients of the two groups were followed up for 3 years.The median disease-free survival time of the study group was 18 months,disease-free survival rate was 69.44%,26 cases in recurrence and transfer,accounted for 24.07%,and 7 cases（6.48%） died;The median disease-free survival time of the control group was 12 months and the disease-free survival rate was 46.15%,18 cases in recurrence and transfer, accounted for 34.62%,and 10 cases（19.23%） died.The median disease-free survival,recurrence and transfer rate of the control group were statistically significant better than those of the control group（χ2 =8.07,4.74,all P〈0.05）.Postoperative adjuvant chemotherapy in patients with adverse reaction was mainly for nausea and vomiting,loss of appetite,pigmentation and hair loss up to see, but were comparatively light, and very little serious most patients could be tolerated.Conclusion The postoperative adjuvant chemotherapy for patients with stageⅡ/Ⅲcolon cancer can reduce postoperative recurrence,metastasis,improve patients＇survival time,prolong patient life.
出处
《中国基层医药》
CAS
2014年第21期3267-3269,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
结肠肿瘤
抗肿瘤联合化疗方案
Colonic Neoplasms Antineoplastic Combined Chemotherapy Protocols
